more images

FDA advisers unanimously back GlaxoSmithKline drug for kidney cancer, despite liver risks

FDA panel unanimously backs Glaxo cancer drug

GAITHERSBURG, Md. — Federal health advisers said Monday an experimental kidney cancer drug from GlaxoSmithKline PLC can benefit patients by slowing the disease, despite some risk of liver damage.

FDA notes liver damage risks with GlaxoSmithKline’s kidney cancer drug

FDA questions safety of Glaxo kidney cancer drug

WASHINGTON — Federal regulators said Thursday an experimental kidney cancer drug from GlaxoSmithKline may cause liver problems, potentially outweighing its ability to slow the disease.